Neurofibrillary tangles (NFT) in Alzheimer's disease (AD) are composed of abnormally phosphorylated tau proteins. Many phosphorylation sites have been reported in the AD brain, and NFT distribution was now roughly classified into 3 stages by Braak stage; this classification is based on pathological studies using the specific silver impregnation technique. The aim of our study was to examine the regional distribution of differently phosphorylated tau proteins with 5 site-specific monoclonal antibodies against the tau proteins, AT8, AT180, HT7, Tau2 and Tau5. We then compared our findings with those obtained from silver-stained NFT in an attempt to clarify the relationship between abnormal phosphorylation sites of the tau protein and NFT development. AT180 and AT8 labeled the highest and Tau2 the lowest density of NFT in any regions, while Tau5 and HT7 showed inconsistent distribution. In the limbic cortex, cornu ammonis, entorhinal cortex and cingulate cortex, silverstained NFT density significantly correlated with density of NFT labeled with the 5 anti-tau antibodies, but cerebral isocortices showed heterogenous patterns of taupositive NFT. Quantification of tau-positive regional NFT density showed that the AD-associated phosphorylation process progresses from the C-terminal to the N-terminal of the amino acid sequence, and correlation of Gallyas-stained NFT density with tau-labeled NFT density was more significant in the limbic cortices than the cerebral isocortices, which implies that stereotypical phosphorylation occurs in the limbic structures.
Introduction
Alzheimer disease (AD) is a major neurodegenerative disorder that causes dementia in elderly people. Neurofibrillary tangles (NFT) and ß-amyloid protein (BAP) deposits forming senile plaques are a pathological hallmark of AD. NFT are composed of paired helical filaments (PHF) in which the tau protein is abnormally phosphorylated. The tau protein is a microtubule-associated protein in the adult human brain consisting of 6 isoforms ranging in length from 352 to 441 amino acid sequences. It plays an ongoing part in the physiological phosphorylation and dephosphorylation process for the assembly and disassembly of microtubules, and thus performs an essential function in the maintenance and stability of microtubules. In a range of neurodegenerative disorders subsumed under tauopathy as well as AD, abnormally hyperphosphorylated tau proteins transform cytoskeletal mate-rials into insoluble fibril structures. In AD, the abnormally hyperphosphorylated tau protein is located in the PHF, neuropil threads and neuritic plaques, which form the pathological cytoskeletal substrates in AD-affected brains.
NFT in AD develop initially from the entorhinal cortex, extend to the limbic allocortex and finally to the isocortex; this NFT evolution is roughly classified into 3 stages, i.e. the transentorhinal, limbic, and neocortical stage, which are believed to correspond to the severity of the clinical manifestations. This classification of the NFT stages depends on the results of pathological examinations using the silver impregnation technique specific to PHF. Abnormal phosphorylation of tau proteins occurs at different sites of the amino acid sequences of tau in AD, while the AD-associated abnormal phosphorylation occurs at serine (Ser) 202 and is predominant in the neurites [1, 2] . Some of these hyperphosphorylated sites have been identified with different phosphorylation-dependent monoclonal anti-tau antibodies. It is therefore not yet fully understood how abnormal phosphorylation sites are associated with the spreading of NFT.
In this study, we quantitatively examined NFT density at 8 cerebral regions in clinicopathologically verified AD brains by using 5 site-specific monoclonal anti-tau antibodies to label NFT. These results of our examination are expected to clarify the regional distribution of differently phosphorylated tau proteins, which should help us understand the relationship between the abnormal phosphorylation site of the tau protein and NFT evolution in AD.
Materials and Methods
Seven brains from patients with non-familial AD and 3 control brains were pathologically examined [3, 4] . These AD brains met with the diagnostic criteria of the CERAD [5] and of Khachaturian [6] . The average age at death was 62.5 years and the average duration of the disease was 4.7 years [3, 4] . Brains were removed at autopsy, fixed in 10% formalin and embedded in paraffin wax. Representative sections were taken from the cerebrum, cerebellum, brain stem and spinal cord of AD patients. The sections were cut 7 Ìm thick and hemispheric cerebral sections at the level of the temporal pole, head of the caudate nucleus, lateral geniculate body, precuneus and calcarine were prepared. The sections were stained with hematoxylin and eosin, Luxol fast blue and cresyl violet (Klüver-Barrera), and Bodian and Holzer techniques were used for routine pathological examinations. Immunolabeling employed an avidin-biotin-peroxidase complex method with a Vectastain avidin-biotin-peroxidase complex kit (Vector Laboratories, Burlingame, Calif., USA), using 5 mouse monoclonal antibodies, Tau2 (Novocastra, UK, 1:200), Tau5 (Pharmingen, USA, 1:2,000), AT8 (Innogenetics, USA, 1:2,000), AT180 (Innogenetics, 1:2,000) and HT7 (Innogenetics, 1:100). For BAP labeling, the sections were pretreated with 99% formic acid for 5 min and then processed with an anti-BAP (clone 4G8, diluted 1:2,000; Sennetek, USA). 0.0002% H 2 O 2 were added to 0.01% 3,3)-diaminobenzidine tetrahydrochloride solution in 0.005 M Tris-HCl buffer, while 0.005 M imidazole was used as the chromogen. The cerebral regions examined included sectors 1-4 of the cornu ammonis (CA), the entorhinal cortex, temporal neocortex, anterior cingulate gyrus, inferior parietal lobe, occipital cortex (the parastriate and peristriate areas) and lateral prefrontal lobe. Quantitative examination was performed on matched regions for NFT counting. In each region, 5 nonoverlapping visual fields (!20 objective and !10 eyepiece, 0.00168 mm 2 ) were randomly selected and monitored with a Polaroid Microscopic Camera (Polaroid Corporation, Cambridge, Mass., USA) attached to a Nikon ECLIPS E600 and interfaced with Macintosh Adobe Photoshop. Gallyas-stained NFT included intracellular tangles and extracellular ghost tangles, while tau-labeled NFT included NFT with a tangle-like appearance and diffuse cytoplasmic labeling. Statistical analyses employed two-way ANOVA, regression analysis and unpaired Student's t test with SPSS and Stat View, both for Windows. Statistical significance was set at p ! 0.05.
Results
The 7 AD cases examined showed that NFT involvement of the isocortical regions corresponded with stage V or VI [3, 4] . BAP labeling detected sufficient numbers of neuritic plaques to meet the pathological criteria. A certain number of NFT showed different morphologies depending on the anti-tau antibodies used. Tau2-and HT7-positive NFT showed mostly a tangle-like morphology and a certain number of NFT labeled with AT8, AT180 and Tau5 presented diffuse cytoplasmic labeling ( fig. 1 ). Intracytoplasmic and extracellular NFT were stained with the Gallyas technique. In some normal controls, a limited number of Gallyas-stained NFT were present in the entorhinal cortex, and only a small number of tau-positive NFT were scattered throughout the cerebral cortex. Thus, it became clear that the density of tau-labeled or Gallyasstained NFT was higher in AD cases than normal controls, prompting us to perform a quantitative analysis of NFT density in AD cases. The distribution of the density of NFT labeled with the various anti-tau antibodies and stained with the Gallyas technique is summarized in figure 2. Gallyas-stained NFT were distributed throughout the 7 regions which define NFT stages in AD, and quantification of their density showed that NFT density was the highest, followed by that of the entorhinal cortex, CA, cingulate gyrus, parietal cortex, occipital cortex, temporal cortex and prefrontal cortex. The unpaired t test showed that the entorhinal cortex, CA and cingulate gyrus contained NFT with the three highest densities and the NFT density in all the other cortical regions was lower (table 1) , which is compatible with NFT development in terms of the Braak stage [7] . Density of NFT positive for AT180 was significantly higher than that of NFT positive for HT7 (t = 4.253, p ! 0.0001), Tau2 (t = 11.743, p ! 0.0001) and Tau5 (t = 5.322, p ! 0.0001), while it was lower than the density of Gallyas-stained NFT (t = -2.504, p = 0.0127) when the NFT density of all regions is taken into account. Evaluation of AT180-positive NFT density according to region showed higher density in the CA and the entorhinal cortex than in the other regions and the lowest density was observed in the occipital cortex. NFT density in the temporal isocortex was significantly higher than that in the parietal, prefrontal and occipital cortex (table 1). NFT labeling by AT180 and AT8 showed similar tendencies in their regional density distribution except in the occipital cortex where AT8 detection of NFT was more sensitive than that by AT180 ( fig. 2) .
For HT7 labeling, the density of NFT in the CA was significantly higher than that in the parietal (t = 3.649, p = 0.0002) and occipital cortex (t = 3.838, p = 0.0005), while that in the entorhinal cortex was similar to that in the CA (table 1) . Density of Tau5-positive NFT in the CA and entorhinal cortex was higher than that in the parietal (vs. CA: t = 4.998, p ! 0.0001; vs. entorhinal: t = 4.266, p ! 0.0001), prefrontal (vs. CA: t = 3.329, p = 0.0016; vs. entorhinal: t = 2.680, p = 0.0098) and occipital cortex (vs. CA: t = 3.914, p = 0.0004; vs. entorhinal: t = 3.542, p = 0.0011). The regional NFT labeling pattern was similar for Tau5 and Tau2, but Tau2 was more prominent in the CA, entorhinal cortex and cingulate gyrus. The distribution of NFT expression for each of the tau proteins was analyzed in terms of these 7 regions (table 2). The CA and entorhinal cortex contained a higher density of NFT positive for AT180 and AT8 than for HT7, Tau5 and Tau2  (table 2) . In the temporal cortex, density of NFT positive for Tau2 was the lowest (AT180: t = 10.475, p ! 0.0001; AT8: t = 7.316, p ! 0.0001; HT7: t = 5.721, p ! 0.0001; Tau5: t = 5.077, p ! 0.0001). In the cingulate and temporal cortex, Tau2-positive NFT showed the lowest density (in the temporal cortex, AT180: t = 10.475, p ! 0.0001; AT8: t = 7.316, p ! 0.0001; HT7: t = 5.721, p ! 0.0001; Tau5: t = 5.077, p ! 0.0001; in the cingulate cortex, AT180: t = 3.407, p = 0.0013; AT8: t = 2.725, p = 0.0090; HT7: t = 2.637, p = 0.0112; Tau5: t = 2.135, p = 0.0379) compared with the density of NFT positive for the other anti-tau antibodies. In the prefrontal cortex, there were no significant statistical differences in the densities of NFT positive for each of the anti-tau antibody among the 7 regions. In the parietal cortex, as in the temporal cortex, density of Tau2-positive NFT was the lowest.
Regression analysis was performed to determine what density of NFT labeled with anti-tau antibodies significantly correlated with the density of Gallyas-stained NFT. In the CA, density of Gallyas-stained NFT correlated significantly with that of NFT labeled with all 5 anti-tau antibodies (AT180: r = 0.543, p = 0.0019; AT8: r = 0.887, Nakano/Kobayashi/Sugimori/Shimazaki/ Miyazu/Hayashi/Furuta positive NFT density showed this correlation (r = 0.567, p = 0.0120). In the prefrontal cortex, Gallyas-stained NFT density correlated significantly with the density of AT8-positive (r = 0.766, p ! 0.0001) and Tau2-positive (r = 0.735, p ! 0.0001) NFT. When all the regions were included in the analysis, the density of Gallyas-stained NFT showed significant correlation with the density of NFT positive for AT180 (r = 0.502, p ! 0.0001), AT8 (r = 0.762, p ! 0.0001), HT7 (r = 0.332, p ! 0.0001), Tau2 (r = 0.661, p ! 0.0001), and Tau5 (r = 0.330, p ! 0.0001).
Discussion
Postmortem delay in our AD cases ranged from 3.0 to 8.4 h, as documented in our previous two studies on glial and neuronal apoptosis in the AD brain [3, 4] , which was found to result in no bias for tau immunohistochemistry [8] . Gallyas-stained NFT was distributed predominantly in the CA, entorhinal cortex and cingulate cortex where NFT develop in the early stage of AD, which is compatible with evidence from extensive studies of regional dis-Nakano/Kobayashi/Sugimori/Shimazaki/ Miyazu/Hayashi/Furuta tribution of NFT [9] [10] [11] [12] [13] [14] [15] , particularly in terms of the Braak stage for NFT [7] . Phosphorylation sites of amino acid sequences of the tau protein are known to number 45, and among them, there are 19 sites of abnormal phosphorylation that are specific in AD. AT180 recognizes Thr231 on the longest amino acid sequence [16] , AT8 on Ser202 and threonine (Thr) 205 [17] , Tau2 on alanine (Ala) 95 to Ala108 [18] [19] [20] , Tau5 in the central zone of the sequence [21] , and also reacts with the nonphosphorylated as well as the phosphorylated forms of tau, and HT7 on Ser159 to Ser163 [22] . These findings showed that in our study, at least 6 phosphorylation sites could be examined. AT8 has been pathologically shown to label pretangle neurons and intracellular NFT, but not extracellular ghost tangles [23] , while the Gallyas impregnation technique stains intracellular NFT, ghost tangles and a limited number of pretangle neurons [24] . This technique has been shown to also react with twisted structures of paired helical filaments where abnormally phosphorylated tau proteins are tightly attached [25] . In our study, AT180-positive NFT density was especially predominant in the CA, entorhinal and cingulate cortex, as it was when all regions were included. AD-associated abnormal phosphorylation starts at Ser199 and Ser202 in the neuropil threads, but some studies [26] [27] [28] reported that the earliest abnormal phosphorylation was shown to occur around Thr231 in AD and the extent of phosphorylation was greater than at other sites. AT180 as well as AT8 labeled few neuritic profiles in the neuropil and the quantitative results of our study indicate that Thr231 is an initial phosphorylation site of neuronal cytoplasmic NFT associated with the AD-related phosphorylation process. Statistical differences in the density of NFT positive for the 5 monoclonal anti-tau antibodies among the regions examined indicate that sequential phosphorylation of tau proteins occurs. Ser202 and Thr205 recognized by AT180 and Thr231 by AT8 are the initial phosphorylation sites and may be simultaneously phosphorylated, and amino acids of Ala95 to Ala108 recognized by Tau2 are the last sites. Phosphorylation of Ser159 to Ser163 recognized by HT7 appears to follow phosphorylation of Ser202, Thr205 and Thr231. Thus, it is likely that AD-associated abnormal phosphorylation progresses from the C-terminal to the N-terminal of the tau protein amino acid sequence within intracellular NFT. In our study, neuritic tau expression was not evaluated because of the difficulty of its quantification. Kimura et al. [1] used tau immunohistochemistry employing 5 monoclonal antibodies that recognize Ser199/202, Ser231, Ser369, Ser409 and Ser422 to identify 3 stages of NFT, i.e. pretangles, tangles and ghost tangles. The antibodies recognizing Ser409 and Ser422 near the C-terminal labeled more neuropil threads than did the antibodies recognizing Ser231 or Ser396 near the N-terminal. The study by Kimura et al. [1] thus supports part of our findings. In the CA, entorhinal cortex and cingulate cortex, the density of Gallyas-stained NFT significantly correlated with that of NFT positive for all of the anti-tau antibodies, which indicates uniform phosphorylation of tau. However, the parietal, occipital and prefrontal cortex did not show such a correlation; instead the density of tau-labeled and Gallyas-stained NFT showed that the density of Gallyas-stained NFT correlated only with Tau2 in the parietal cortex, HT7 in the occipital cortex and AT8 and Tau2 in the prefrontal cortex. This difference was partly due to the difference in tau-labeled NFT morphologies as HT7 and Tau2 tended to label tangle-like NFT with a neuritic profile, and 3 regions involved were categorized as part of the limbic cortex. Although further investigation with more cases is needed to confirm whether these tau protein expressions predominate in these neocortical areas, this finding suggests that AD-associated abnormal phosphorylation occurs stereotypically and sequentially in the limbic cortex but does so randomly in the neocortical regions. Neocortical NFT involvement and regional distribution of certain types of tau protein expression in the neocortex in AD do not always show a stereotypical pattern [9, 10, 12, 13, 29, 30] . NFT showed a heterogenous pattern along the rostrocaudal axis in the cerebral neocortex, while a uniform pattern of tau isoforms was found in the limbic cortex, parietal neocortex and temporal neocortex [12] . Another study reported that NFT were characterized by a hierarchical pattern, in which PHF-tau proteins were more randomly distributed in the neocortex and association cortices including the prefrontal, parietal and temporal cortex, than in the entorhinal cortex, hippocampus and inferior temporal cortex [14] . These two studies imply that tau phosphorylation occurs in a regular pattern in the limbic cortex but irregularly in the neocortex or association areas. This is applicable particularly to clinical variants of AD that show focal accentuation of NFT, such as Balint syndrome and right parietal lobe syndrome, in which severity of neocortical NFT considerably differs from case to case [30] [31] [32] . This means that the random pattern of NFT development in the neocortex may be attributable to the irregular expression of HT7 or Tau2.
In conclusion, AD-associated abnormal phosphorylation of the tau protein progresses from the C-terminal to the N-terminal, and a uniform phosphorylation pattern of tau in the limbic cortex and random phosphorylation in the cerebral isocortices are characteristics of NFT in AD.
